Contract R&D to Identify Drugs that Target Human Topo I, Topo II, Bacterial Topo IV and DNA Gyrase

Experience. Rapid Turn-Around. Publication Quality. TopoGEN has >20 yrs. experience in the area as a Contract Research Organization and we stand behind our results. We guarantee clear, cosmetic data and unambiguous interpretations. You will receive a publication quality product. We are seasoned veterans in the arena of in vitro testing. More importantly, we can help […]

SBIR-Funded Alliance to Conquer the Cold-Chain

July 20, 2018 TopoGEN was featured in the local press in order to showcase our collaboration with Nanoly Bioscience based out of Boulder.  Nanoly has developed a polymer-based cage (the NanoShield) that can protect labile products from fluctuations in temperature and possibly obviate need for expensive dry ice transit around the world.  TopoGEN is going to field […]

Update on the role of topotecan in the treatment of non-small cell lung cancer.

Non-small cell lung cancer (NSCLC) is an aggressive disease that is generally resistant to chemotherapy. As a result, the prognosis for patients with NSCLC is poor. Currently, platinum-based regimens are the standard of care for patients with advanced NSCLC. However, these regimens are associated with severe and often cumulative hematologic and nonhematologic toxicities, limiting dose […]

0
    0
    Your Cart
    Your cart is emptyReturn to Shop